Coronary Revascularization in Patients With Cancer

Curr Treat Options Cardiovasc Med. 2023;25(6):143-158. doi: 10.1007/s11936-023-00982-9. Epub 2023 Apr 21.

Abstract

Purpose of review: The treatment of coronary artery disease (CAD) in cancer patients is an evolving landscape. Recent data emphasizes the importance of aggressive management of cardiovascular risk factors and diseases in improving cardiovascular health in this unique group of patients regardless of cancer type or stage.

Recent findings: Novel cancer therapeutics such as immune therapies and proteasome inhibitors have been associated with CAD. Recent stent technologies may safely allow for shorter duration (< 6 months) of dual antiplatelet therapy post-percutaneous coronary interventions. Intracoronary imaging may be useful in the decision making process in terms of stent positioning and healing.

Summary: Large registry studies have partially filled a gap left by the lack of randomized controlled trials in the treatment of CAD in cancer patients. Cardio-oncology is gaining traction as a major sub-specialty in the cardiology field given the release of the first European Society of Cardiology - Cardio-oncology guidelines in 2022.

Keywords: ACS; Acute coronary syndrome; CAD; Cancer; Cardio-oncology; Coronary artery disease; Myocardial infarction; PCI; Radiation.

Publication types

  • Review